AstraZeneca Stock Leads 3 Cash Flow Picks Trading Below Fair Value

Record export growth in hubs like Hong Kong shows how global cash flows are still moving, even as headlines focus on inflation and higher yields. When trade holds up, companies that convert sales into solid cash generation can look interesting if their shares trade below estimated fair value. This article highlights three stocks from the Undervalued Stocks Based On Cash Flows screener that may appeal to patient value hunters.

The stocks below are just a starting sample, and the full screen surfaced 45 more companies with equally focused cash flow stories that are not covered here. To identify and analyze your own highest conviction ideas from this universe, head straight into the Undervalued Stocks Based On Cash Flows screener.

AstraZeneca (LSE:AZN)

AstraZeneca is a global biopharmaceutical company that discovers, develops and sells prescription medicines, with a strong focus on oncology and cardiovascular, renal and metabolism therapies that generate recurring, high-revenue drug sales and support discounted cash flow based analysis. All of its reported revenue of about $61.4b comes from pharmaceuticals, reflecting a broad but commercially focused product portfolio rather than ancillary businesses. The stock is a large cap with a market value of roughly £187.8b.

For a cash flow focused investor, AstraZeneca offers a mix of blockbuster oncology and cardiovascular drugs that already support solid earnings, alongside a late stage pipeline in cancer and rare diseases that could extend those cash flows for years if trials and approvals keep landing. At the same time, a high debt load, heavy R&D spending and reliance on a handful of key drugs mean any setback on pricing, regulation or patent protection can hit that cash flow story hard. The company currently screens as trading well below an SWS DCF estimate. If you care about whether that gap is justified or temporary, AstraZeneca is worth a closer look.

AstraZeneca’s oncology and cardiovascular portfolio, a key driver of cash generation, appears out of sync with a stock that screens well below an SWS DCF estimate. Get the fuller cash flow story and risk trade offs in the DCF valuation analysis for AstraZeneca

Foresight Group Holdings (LSE:FSG)

Foresight Group Holdings is an infrastructure and private equity manager, with its Real Assets division at the heart of the cash flow story through renewable energy projects that sell power under contracts and receive subsidies. Real Assets generated about £114.8 million of revenue versus £50.1 million from Private Equity, so most fees currently come from infrastructure focused mandates rather than buyouts and growth deals. The stock is a mid cap with a market value of roughly £548 million.

Foresight Group Holdings sits in this cash flow focused screen because its renewable infrastructure funds and assets are designed to produce long term, contracted income that feeds into DCF style valuations. The shares trade at a discount to the screener’s estimate of fair value. That stable base is paired with growing AUM, high reported returns on equity and an active buyback program that aims to lift earnings per share. Investors still need to weigh rising costs, reliance on performance fees and policy risk around green subsidies. For anyone interested in how those moving parts could affect future cash generation and whether the discount can close, Foresight is worth closer attention.

Foresight Group Holdings has renewable cash flows that some investors may be treating like any other asset manager. The stock screens at a discount, and its real story sits inside the analysis report for Foresight Group Holdings

BAE Systems (LSE:BA.)

BAE Systems is a £59.4b defense and aerospace company that earns its money from a broad mix of electronics, combat vehicles, aircraft and maritime programs, with Electronic Systems and Air each generating about £7.8b and £7.7b of revenue, and Maritime close behind at £6.7b. The clearest fit with this cash flow focused screener comes from its Maritime segment, where long term contracts for Offshore Patrol Vessels, submarines and naval support provide multi year, contract backed cash flows that support discounted cash flow style valuations. For investors, that scale and diversification sit alongside a market value that still reflects a discount to cash flow based fair value estimates.

BAE Systems gives you something many industrials cannot offer: multi year visibility on cash flows from large naval programs in the Maritime segment, plus a £75b order backlog across next generation aircraft, munitions and electronic warfare. The stock screens at a discount to fair value on SWS cash flow estimates. Forecasts in the market point to double digit annual earnings growth and improving returns on equity, yet recent news also shows the trade offs. A US export control fine and ongoing ESG and regulatory scrutiny highlight how dependent BAE is on government contracts and compliance. If you want to understand whether long duration defense cash flows outweigh those risks for your portfolio, this is a story worth unpacking in more detail.

BAE Systems has contract backed cash flows and a £75b backlog that some investors may still be underestimating. See how the long term earnings story lines up in the analyst forecasts for BAE Systems

Seeking Fresh Alternatives Beyond These Picks

New breakout stories and under the radar stocks often move first while attention sticks to the headlines. Spot momentum shifts before the crowd catches up and act now.

• Track income opportunities that can keep paying you while prices move by scanning the curated list of 6 dividend fortresses before yields change.
• Look into the early wave in AI infrastructure spending and find potential beneficiaries with the hand picked 55 AI infrastructure stocks while they remain under the radar for now.
• Review the focused 37 robotics and automation stocks and filter for companies whose stories still look fresh before interest turns to other areas.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com